Cargando…
Wells–Dawson phosphotungstates as mushroom tyrosinase inhibitors: a speciation study
In order to elucidate the active polyoxotungstate (POT) species that inhibit fungal polyphenol oxidase (AbPPO4) in sodium citrate buffer at pH 6.8, four Wells–Dawson phosphotungstates [α/β-P(V)(2)W(VI)(18)O(62)](6−) (intact form), [α(2)-P(V)(2)W(VI)(17)O(61)](10−) (monolacunary), [P(V)(2)W(VI)(15)O(...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481536/ https://www.ncbi.nlm.nih.gov/pubmed/34588468 http://dx.doi.org/10.1038/s41598-021-96491-5 |
_version_ | 1784576693728444416 |
---|---|
author | Lampl, Raphael Breibeck, Joscha Gumerova, Nadiia I. Galanski, Mathea Sophia Rompel, Annette |
author_facet | Lampl, Raphael Breibeck, Joscha Gumerova, Nadiia I. Galanski, Mathea Sophia Rompel, Annette |
author_sort | Lampl, Raphael |
collection | PubMed |
description | In order to elucidate the active polyoxotungstate (POT) species that inhibit fungal polyphenol oxidase (AbPPO4) in sodium citrate buffer at pH 6.8, four Wells–Dawson phosphotungstates [α/β-P(V)(2)W(VI)(18)O(62)](6−) (intact form), [α(2)-P(V)(2)W(VI)(17)O(61)](10−) (monolacunary), [P(V)(2)W(VI)(15)O(56)](12−) (trilacunary) and [H(2)P(V)(2)W(VI)(12)O(48)](12−) (hexalacunary) were investigated. The speciation of the POT solutions under the dopachrome assay (50 mM Na-citrate buffer, pH 6.8; L-3,4−dihydroxyphenylalanine as a substrate) conditions were determined by (183)W-NMR, (31)P-NMR spectroscopy and mass spectrometry. The intact Wells–Dawson POT [α/β-P(V)(2)W(VI)(18)O(62)](6−) shows partial (~ 69%) disintegration into the monolacunary [α(2)-P(V)(2)W(VI)(17)O(61)](10−) anion with moderate activity (K(i) = 9.7 mM). The monolacunary [α(2)-P(V)(2)W(VI)(17)O(61)](10−) retains its structural integrity and exhibits the strongest inhibition of AbPPO4 (K(i) = 6.5 mM). The trilacunary POT [P(V)(2)W(VI)(15)O(56)](12−) rearranges to the more stable monolacunary [α(2)-P(V)(2)W(VI)(17)O(61)](10−) (~ 62%) accompanied by release of free phosphates and shows the weakest inhibition (K(i) = 13.6 mM). The hexalacunary anion [H(2)P(V)(2)W(VI)(12)O(48)](12−) undergoes time-dependent hydrolysis resulting in a mixture of [H(2)P(V)(2)W(VI)(12)O(48)](12−), [P(V)(8)W(VI)(48)O(184)](40−), [P(V)(2)W(VI)(19)O(69)(H(2)O)](14−) and [α(2)-P(V)(2)W(VI)(17)O(61)](10−) which together leads to comparable inhibitory activity (K(i) = 7.5 mM) after 48 h. For the solutions of [α/β-P(V)(2)W(VI)(18)O(62)](6−), [α(2)-P(V)(2)W(VI)(17)O(61)](10−) and [P(V)(2)W(VI)(15)O(56)](12−) the inhibitory activity is correlated to the degree of their rearrangement to [α(2)-P(V)(2)W(VI)(17)O(61)](10−). The rearrangement of hexalacunary [H(2)P(V)(2)W(VI)(12)O(48)](12−) into at least four POTs with a negligible amount of monolacunary anion interferes with the correlation of activity to the degree of their rearrangement to [α(2)-P(V)(2)W(VI)(17)O(61)](10−). The good inhibitory effect of the Wells–Dawson [α(2)-P(V)(2)W(VI)(17)O(61)](10−) anion is explained by the low charge density of its protonated forms H(x)[α(2)-P(V)(2)W(VI)(17)O(61)]((10−x)−) (x = 3 or 4) at pH 6.8. |
format | Online Article Text |
id | pubmed-8481536 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-84815362021-10-01 Wells–Dawson phosphotungstates as mushroom tyrosinase inhibitors: a speciation study Lampl, Raphael Breibeck, Joscha Gumerova, Nadiia I. Galanski, Mathea Sophia Rompel, Annette Sci Rep Article In order to elucidate the active polyoxotungstate (POT) species that inhibit fungal polyphenol oxidase (AbPPO4) in sodium citrate buffer at pH 6.8, four Wells–Dawson phosphotungstates [α/β-P(V)(2)W(VI)(18)O(62)](6−) (intact form), [α(2)-P(V)(2)W(VI)(17)O(61)](10−) (monolacunary), [P(V)(2)W(VI)(15)O(56)](12−) (trilacunary) and [H(2)P(V)(2)W(VI)(12)O(48)](12−) (hexalacunary) were investigated. The speciation of the POT solutions under the dopachrome assay (50 mM Na-citrate buffer, pH 6.8; L-3,4−dihydroxyphenylalanine as a substrate) conditions were determined by (183)W-NMR, (31)P-NMR spectroscopy and mass spectrometry. The intact Wells–Dawson POT [α/β-P(V)(2)W(VI)(18)O(62)](6−) shows partial (~ 69%) disintegration into the monolacunary [α(2)-P(V)(2)W(VI)(17)O(61)](10−) anion with moderate activity (K(i) = 9.7 mM). The monolacunary [α(2)-P(V)(2)W(VI)(17)O(61)](10−) retains its structural integrity and exhibits the strongest inhibition of AbPPO4 (K(i) = 6.5 mM). The trilacunary POT [P(V)(2)W(VI)(15)O(56)](12−) rearranges to the more stable monolacunary [α(2)-P(V)(2)W(VI)(17)O(61)](10−) (~ 62%) accompanied by release of free phosphates and shows the weakest inhibition (K(i) = 13.6 mM). The hexalacunary anion [H(2)P(V)(2)W(VI)(12)O(48)](12−) undergoes time-dependent hydrolysis resulting in a mixture of [H(2)P(V)(2)W(VI)(12)O(48)](12−), [P(V)(8)W(VI)(48)O(184)](40−), [P(V)(2)W(VI)(19)O(69)(H(2)O)](14−) and [α(2)-P(V)(2)W(VI)(17)O(61)](10−) which together leads to comparable inhibitory activity (K(i) = 7.5 mM) after 48 h. For the solutions of [α/β-P(V)(2)W(VI)(18)O(62)](6−), [α(2)-P(V)(2)W(VI)(17)O(61)](10−) and [P(V)(2)W(VI)(15)O(56)](12−) the inhibitory activity is correlated to the degree of their rearrangement to [α(2)-P(V)(2)W(VI)(17)O(61)](10−). The rearrangement of hexalacunary [H(2)P(V)(2)W(VI)(12)O(48)](12−) into at least four POTs with a negligible amount of monolacunary anion interferes with the correlation of activity to the degree of their rearrangement to [α(2)-P(V)(2)W(VI)(17)O(61)](10−). The good inhibitory effect of the Wells–Dawson [α(2)-P(V)(2)W(VI)(17)O(61)](10−) anion is explained by the low charge density of its protonated forms H(x)[α(2)-P(V)(2)W(VI)(17)O(61)]((10−x)−) (x = 3 or 4) at pH 6.8. Nature Publishing Group UK 2021-09-29 /pmc/articles/PMC8481536/ /pubmed/34588468 http://dx.doi.org/10.1038/s41598-021-96491-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Lampl, Raphael Breibeck, Joscha Gumerova, Nadiia I. Galanski, Mathea Sophia Rompel, Annette Wells–Dawson phosphotungstates as mushroom tyrosinase inhibitors: a speciation study |
title | Wells–Dawson phosphotungstates as mushroom tyrosinase inhibitors: a speciation study |
title_full | Wells–Dawson phosphotungstates as mushroom tyrosinase inhibitors: a speciation study |
title_fullStr | Wells–Dawson phosphotungstates as mushroom tyrosinase inhibitors: a speciation study |
title_full_unstemmed | Wells–Dawson phosphotungstates as mushroom tyrosinase inhibitors: a speciation study |
title_short | Wells–Dawson phosphotungstates as mushroom tyrosinase inhibitors: a speciation study |
title_sort | wells–dawson phosphotungstates as mushroom tyrosinase inhibitors: a speciation study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481536/ https://www.ncbi.nlm.nih.gov/pubmed/34588468 http://dx.doi.org/10.1038/s41598-021-96491-5 |
work_keys_str_mv | AT lamplraphael wellsdawsonphosphotungstatesasmushroomtyrosinaseinhibitorsaspeciationstudy AT breibeckjoscha wellsdawsonphosphotungstatesasmushroomtyrosinaseinhibitorsaspeciationstudy AT gumerovanadiiai wellsdawsonphosphotungstatesasmushroomtyrosinaseinhibitorsaspeciationstudy AT galanskimatheasophia wellsdawsonphosphotungstatesasmushroomtyrosinaseinhibitorsaspeciationstudy AT rompelannette wellsdawsonphosphotungstatesasmushroomtyrosinaseinhibitorsaspeciationstudy |